To describe the spectrum and associated clinical features of peripheral and cerebral vasculopathy in pediatric patients with neurofibromatosis type 1, children seen at a single center from 2000 to 2010 with appropriate imaging studies were identified. Scans were assessed for vascular disease by 2 pediatric neuroradiologists. Of 181 children, 80 had pertinent imaging studies: 77 had brain imaging, 6 had peripheral imaging, and 3 had both. Vasculopathy was identified in 14/80 children (18%, minimum prevalence of 14/181; 8%). Of those with vascular abnormalities, 2/14 had peripheral vasculopathy (1% minimum prevalence) and 12/14 had cerebrovascular abnormalities (7% minimum prevalence). No associations were found between vasculopathy and common clinical features of neurofibromatosis type 1, including optic pathway glioma, plexiform neurofibroma, skeletal abnormalities, attentiondeficit hyperactivity disorder (ADHD), or suspected learning disability. Both peripheral and cerebral vasculopathy are important complications of pediatric neurofibromatosis type 1 and should be considered in the management of this complex disease.
Neurofibromatosis type 1 is an autosomal dominant genetic disorder caused by mutation in the tumor suppressor gene NF1. 1 The protein product of NF1 is neurofibromin, a guanosine triphosphatase-activating protein that negatively regulates Ras activity. 2, 3 Neurofibromatosis type 1 is characterized by nerve sheath neurofibromas but has a number of additional clinical features. One of these clinical features is vasculopathy, which can occur throughout the body (brain and periphery). [4] [5] [6] [7] The etiology of vascular disease in neurofibromatosis type 1 is not well understood. The neurofibromin protein has been shown to be expressed in the vascular endothelial cell layer as well as in the smooth muscle of the aorta, and it is likely involved in the pathogenesis of neurofibromatosis type 1-associated vasculopathy. 8, 9 Smooth muscle cells that have lost NF1 exhibit an abnormal proliferative response to arterial injury, which may account for the development of obstructive vascular disease in neurofibromatosis type 1. 3 This increased neointima formation in response to mechanical injury has been shown to be mediated by a molecular signaling pathway in NF1þ/-mice that is sensitive to the tyrosine kinase inhibitor imatinib. 10 With this genetic predisposition, vasculopathy in neurofibromatosis type 1 appears to be an acquired condition. The progression of existing vascular lesions, as well as the development of new lesions, has been described in individuals with neurofibromatosis type 1. 11, 12 Yearly blood pressure monitoring is recommended for children with neurofibromatosis type 1 because of the possible development of hypertension associated with renovascular disease, coarctation of the aorta, or other peripheral vascular abnormalities. 13, 14 Screening imaging studies, such as magnetic resonance imaging (MRI) and magnetic resonance angiography of the brain or renovascular imaging, in children without symptoms are not recommended. 13 A better understanding of vascular disease in pediatric neurofibromatosis type 1 would inform the clinical management of these children.
Several studies have examined the prevalence and spectrum of cerebrovascular disease in children with neurofibromatosis type 1. [4] [5] [6] These authors have found that moyamoya syndrome is fairly common, present in 3% to 5% of children with neurofibromatosis type 1 with imaging performed for clinical indications 5, 6 and representing 60% to 70% of children with neurofibromatosis type 1 and cerebrovascular abnormalities. 6 In these studies, children with milder forms of cerebrovascular disease were often asymptomatic. [4] [5] [6] Other types of neurofibromatosis type 1-associated vascular disease, including aortic and renal artery abnormalities, have been discussed in only small case series. 15, 16 Various abnormalities have been reported in vessels of all calibers, but neither the frequency of noncerebral vascular disease in neurofibromatosis type 1 patients nor the association between cerebral and peripheral vasculopathy has been systematically studied. 7 The aim of this study was to describe the spectrum of both peripheral and cerebral vasculopathy in a tertiary care clinical population of pediatric neurofibromatosis type 1 patients, to estimate the minimum prevalence of vasculopathy in this population, and to examine associations between vasculopathy and common features of neurofibromatosis type 1.
Methods

Study Population
The Comprehensive Neurofibromatosis Center at the Johns Hopkins Hospital provides care for children and adults with confirmed neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. In keeping with the current recommendations from the National Neurofibromatosis Foundation Optic Pathway Task Force 17 and the American Academy of Pediatrics, 13 screening or universal imaging is not performed; instead, imaging is requested for clinical concerns. The study population was drawn from the Institutional Review Board-approved Comprehensive Neurofibromatosis Center database that included adults and children seen from July 2000 through June 2010. Inclusion criteria were (1) children 0 to 18 years during the study period who met National Institutes of Health diagnostic criteria for neurofibromatosis type 1 (2) with appropriate imaging (defined below) during the study period. Patients who received intracranial radiation were not excluded. This study was approved by the Institutional Review Board.
To examine associations between vasculopathy and common features of neurofibromatosis type 1, clinical and demographic information for each study patient was obtained from the electronic patient record. For bony deformities, sphenoid wing dysplasia, tibial bowing, and pseudoarthrosis were all included; moderate to severe scoliosis or kyphosis was also reported, defined as a curvature of at least 25 . 18, 19 The presence of physician-diagnosed attention-deficit hyperactivity disorder (ADHD) and/or suspected learning disability (defined as the child having repeated at least 1 grade, having an individual education plan, or attending a special education school) was also recorded. Hypertension was defined as diagnosed by a physician; recorded blood pressures were compared to national guidelines for height, weight, and gender. 20
Imaging
Patients with existing imaging studies completed between 2000 and 2010 were identified. The following imaging studies were used to examine the peripheral vasculature: magnetic resonance angiography of the abdomen and chest, contrast-enhanced computed tomography (CT), CT angiography, or noncerebral conventional angiography of the abdomen and chest. The following imaging studies were examined for vasculopathy of the head and neck: MRI of the brain, magnetic resonance angiography of the brain and/or neck, conventional cerebral angiography, and CT of the neck. Dedicated imaging of the spine was not used for the evaluation of the neck, thoracic, or abdominal vasculature because of the limited and inconsistent ability of these scans to visualize the vasculature. The first and most recent available imaging study of each modality was reviewed to examine the progression of vascular findings over time.
All imaging studies were reviewed independently by 2 pediatric radiologists who are also board certified in neuroradiology; they were blinded to the clinical presentation. 6 Vasculopathy was defined as any abnormality in the cerebral or peripheral vasculature that could not be considered a normal variant. In particular, vessels were examined for stenosis, aneurysm, tortuosity, and the formation of abnormal collateral arterial supply. Appearance of moyamoya vessels, prior ischemic injury, and prior revascularization surgery was noted. The presence of optic pathway glioma, other glioma, plexiform neurofibroma, sphenoid wing dysplasia, and focal areas of abnormal signal intensity (also referred to as unidentified bright objects in neurofibromatosis type 1) was also noted. In cases of disagreement, consensus opinion based on discussion between the 2 radiologists was sought and reported.
Statistical Analysis
Frequency of vasculopathy was described. The authors compared the frequency of cerebral vasculopathy in this study population to those of Rosser et al, 4 Rea et al, 5 and Cairns and North 6 via a binomial comparison of proportions. All comparisons of proportions were analyzed using chi square or Fisher exact test when any value was less than 5. Because of the small number of outcome events, logistic regression was not performed but rather Fisher exact test was used to examine features associated with cerebral vasculopathy, peripheral vasculopathy, and any vasculopathy. The authors conducted analyses using Stata 11.0 (College Station, TX) and considered a P value <.05 to be significant for all analyses.
Results
The authors screened 517 patients in the neurofibromatosis database and found 424 adults and children with a confirmed diagnosis of neurofibromatosis type 1. Of these, 181 were between 0 and 18 years of age. Of this group of 181 children, 80 (44%) had pertinent and available imaging studies completed between 2000 and 2010. Demographic information is summarized in Table 1 . Indications for imaging are tabulated in Table 2 , and clinical characteristics of patients with identified vasculopathy are summarized in Table 3 . All imaging studies were performed for clinical indications except 8 brain MRIs ordered for screening purposes by outside physicians before referral to our neurofibromatosis center. Of the MRI studies examined, 95% were performed using a 1.5-Tesla scanner and 5% on a 3-Tesla scanner. Of 80 children with imaging ( Figure 1 , Flow Chart), 77 (96%) patients had MRIs of the brain and 11 patients had cerebral magnetic resonance angiography. Four children had conventional angiography of the cerebral vasculature to better define severe vasculopathy. Of the 6 children with peripheral imaging, 2 had magnetic resonance angiography of the abdomen/pelvis, 2 had CT angiography, and 2 had conventional angiography of the abdominal aorta or its major branches. Three patients had both central and peripheral imaging studies.
Vasculopathy was identified in 14/80 children (18%) who had imaging, for a minimum prevalence of 14/181 (8%) in the study population. Of 14 children with identified vascular abnormalities, 2 (14%) had abnormalities of the peripheral vasculature and 12 (86%) had cerebral vasculopathy ( Figure 2 ). The minimum prevalence values based on a study population of 181 were 1% and 7% for peripheral and cerebral vasculopathy, respectively. None of the 3 children with central and peripheral imaging had both cerebrovascular and peripheral vascular abnormalities. The mean duration of follow-up, defined as time elapsed between the initial and the most recent imaging study, was 6.3 years with a standard deviation of 4 years. Follow-up images were not available for review, but the child progressed clinically with difficult-to-control hypertension and progression of aortic vasculopathy per outside radiology report. He had surgical revascularization for midaortic syndrome at an outside institution.
Peripheral Vasculopathy
Only 6 of 80 children had pertinent imaging of the peripheral vasculature; 2 of 6 children with appropriate imaging had peripheral vasculopathy and were diagnosed with midaortic syndrome, defined as stenosis of multiple branches of the abdominal aorta. 21, 22 Both of the children with peripheral vasculopathy met national guidelines for stage 2 hypertension: systolic and/or diastolic blood pressure 99th percentile plus 5 mm Hg for age, height, and gender 20 and had fairly dramatic hypertension at presentation with systolic blood pressures >160 mm Hg. There were 3 of 5 children with hypertension who did not have a vascular explanation for their elevated blood pressure (1 child only had a renal duplex ultrasound and brain MRI; he met study inclusion criteria based on brain MRI but did not have appropriate peripheral vascular imaging studies). After undergoing evaluation for pheochromocytoma and other causes of hypertension, these patients were diagnosed with idiopathic hypertension and 2 of the 3 required medical management of their blood pressure. Both children with midaortic syndrome showed progression of their vasculopathy (Table 3 ) and required surgical treatment of their vasculopathy in addition to multiple antihypertensive medications for control of their blood pressure. Both children underwent MRI of the brain and did not have cerebral vasculopathy.
Cerebral Vasculopathy
Cerebral vasculopathy was found in 12 of 77 children who underwent neuroimaging (15%, 95% CI: 8%-26%). Moyamoya syndrome was identified in 5 of 77 (6%) children and was the most common vascular abnormality. Of the children with moyamoya, the most severe form of cerebral vasculopathy, 2 were symptomatic-with clinical stroke in 1 child and transient ischemic attack in the other; 3 children were asymptomatic and were diagnosed with abnormal ''moyamoya vessels'' seen on MRI of the brain done for another indication (concern for optic pathway glioma or headache). One clinically asymptomatic child with moyamoya had a silent stroke (no focal deficits, stroke not suspected) detected on imaging. Both children with overt or silent stroke seen on MRI of the brain had cerebral vasculopathy. Two of the 12 patients with cerebral vasculopathy exhibited progression of their vasculopathy on subsequent imaging. One patient developed moyamoya that became apparent 7 years after serial MRIs for optic pathway glioma were initiated and the other had tortuosity of the intracranial internal carotid artery that progressed over 7 years. Two of 5 children underwent revascularization surgery for moyamoya syndrome. Of the 80 children with imaging, 1 had received cranial radiation therapy for a pontine glioma; this child was subsequently followed for 6 months without evidence of vasculopathy on MRI.
Other Neurofibromatosis Type I-Associated Diagnoses
Of the 77 children with MRI of the brain, 34% had an optic pathway glioma, and other presumed glial brain tumors were seen in 10%; 79% had focal areas of abnormal signal intensity (also called unidentified bright objects). Of the 80 children with imaging who were included in the study population, plexiform neurofibromas were present in 29 children (36%). Bony deformities were found in 19%, and moderate to severe scoliosis or kyphosis was found in 16%. Cognitive and behavior diagnoses were also common, with 29% of patients having physician-diagnosed ADHD and 53% having a suspected learning disability.
Analysis of Associations With Vasculopathy
In this clinic-based population, we found no association with, or predictors of, vasculopathy including gender, focal areas of abnormal signal intensity, plexiform neurofibroma, or the presence of optic pathway glioma. In particular, ADHD and suspected learning disability were not associated with cerebral vasculopathy. Severe hypertension was present in both children with severe vasculopathy of the abdominal aorta. Hypertension was not associated with cerebral vasculopathy.
Comparison to Similar Studies
We did not find other studies that examined the prevalence of peripheral vasculopathy. When comparing these data to the 3 prior studies of cerebral vasculopathy, we report a prevalence that is 8% to 11% higher than the existing data. Cairns and North 6 found cerebral vasculopathy in 7 of 144 children (5%, 95% CI: 2%-10%) with neurofibromatosis type 1 who underwent brain MRI compared with 12 of 77 children (15%, 95% CI: 8%-26%) in this current study, a 10% difference in proportions, which was significant (95% CI: 0.9%-18%, P ¼ .01). Rosser et al 4 noted cerebral vasculopathy in 8 of 316 children (2.5%, 95% CI: 2%-5%) with neurofibromatosis type 1 who had MRI of the brain; again, compared with the prevalence of vasculopathy in our study, there is an 11% difference in proportions, which was significant (95% CI: 4%-19%, P < .0001). Finally, Rea et al 5 noted cerebral vasculopathy in 17 of 266 children (6%, 95% CI: 4%-10%) with neurofibromatosis type 1, an 8% difference in proportions, which also was significant (95% CI: 4%-16%, P ¼ .02).
Discussion
Vasculopathy is an increasingly recognized complication of neurofibromatosis type 1. However, the spectrum of vascular abnormalities that may present in pediatric neurofibromatosis type 1 has not been well characterized, particularly for peripheral lesions. The authors report a minimum prevalence rate of 8% for both peripheral and cerebral vasculopathy associated with pediatric neurofibromatosis type 1, based on confirmed findings in 14 of 181 children seen in a large neurofibromatosis clinic. At our center, the minimum prevalence of symptomatic peripheral vascular abnormalities was 2 of 181 children (1%) with neurofibromatosis type 1. The minimum prevalence of symptomatic cerebrovascular disease was 2 of 181 children (1%). When children with asymptomatic as well as symptomatic cerebrovascular disease were included, the minimum prevalence was 12 of 181 children (7%) with a prevalence of 15% in 77 children with appropriate neuroimaging. The actual prevalence of vasculopathy may be greater, as only 80 children (44%) of the clinic population underwent imaging studies, and even fewer had dedicated vascular imaging of the brain (11/181, 6%) or peripheral vasculature (6/181, 3%). Cerebral vasculopathy was assessed primarily by abnormal flow voids on MRI; our study is similar to prior reports of cerebral vasculopathy in this regard. In Rosser et al 4 Cerebral vasculopathy was often asymptomatic-of the patients with vascular abnormalities identified on neuroradiologic studies, only 2/12 (17%) presented with classic strokelike symptoms. The remaining patients were discovered incidentally on scans performed for other reasons (Table 1) ; for example, MRI of the brain was done for headache (1 patient) or with concerns for optic pathway glioma (4 patients). Four children ( Table 3 , nos. 7, 9, 11, and 12) were found to have previously unidentified vascular abnormalities (all asymptomatic vessel tortuosity or elongation). In children imaged for clinical indications, 12 of 77 (15%) with MRI of the brain had cerebral vasculopathy, which is a higher frequency than has been reported in other neurofibromatosis clinic populations (2%-6%), but is still within the 95% confidence intervals of 2 of 3 prior publications. [4] [5] [6] Review of all scans by neuroradiologists (rather than relying on previous radiology reports) may have increased this study's sensitivity for mild vascular anomalies, contributing to our higher prevalence of vasculopathy.
Moyamoya syndrome was the most common vascular finding in this study and has been shown to be a common vasculopathy seen in neurofibromatosis type 1. 6 Of the 5 patients with moyamoya, 3 had no symptoms of stroke or transient ischemic attack at the time of diagnosis (although 1 had silent stroke on brain MRI done for optic pathway glioma monitoring), whereas 2 had symptomatic cerebral ischemia (stroke or transient ischemic attack).
Peripheral vasculopathy is more elusive. Only children with significantly elevated blood pressures were regularly evaluated via imaging. Children with milder blood pressure elevation were often not imaged, so the current results represent a minimum prevalence of peripheral vasculopathy in children with neurofibromatosis type 1. Two patients (nos. 13 and 14) were found to have midaortic syndrome, which was the only peripheral lesion identified in our study population. Midaortic syndrome refers to aortic coarctation at the level of the distal thoracic or abdominal aorta, and has been reported in association with neurofibromatosis type 1. 14, 21, 22 Midaortic syndrome is frequently accompanied by renal and visceral artery stenosis, and most patients present with uncontrollable hypertension (as was the case with the 2 affected children in this study). 23 Lin et al 24 reviewed more than 2500 adult and pediatric patients in the National Neurofibromatosis Foundation International Database for cardiovascular malformations, including aortic coarctation, and found an overall frequency of 2%. To our knowledge, ours is the first study to consider all types of cerebral and peripheral vascular abnormalities in children with neurofibromatosis type 1. In this small sample, we found that symptomatic peripheral vascular problems (n ¼ 2) were not associated with cerebrovascular problems.
Cerebral vasculopathy was not strongly associated with optic pathway glioma in children with neurofibromatosis type 1, contrary to previous studies. One explanation for this lack of association is simply that our sample size is small. Another possibility is that no child with vasculopathy in this study was treated with cranial radiation. Radiation is a known cause of cerebral vasculopathy. 25 Finally, patients with optic pathway glioma are more likely to have serial imaging to monitor for optic pathway glioma progression, and therefore a progressive cerebral vasculopathy may be identified when there is not a true statistical association. Indeed, 3 cases of moyamoya in this study were discovered incidentally during routine scans for optic pathway glioma monitoring. 5 There are several limitations to this study. A selection bias is inherent to the recruitment of patients from a tertiary care clinic. Our study population may have included a greater number of patients with more advanced or difficult-to-manage disease and therefore more children with vasculopathy; however, overall we seemed to have a fairly typical population of children with neurofibromatosis type 1 in that 49% of cases were familial, 29% had ADHD, 53% had suspected learning disability, and 36% had plexiform neurofibroma. 26, 27 As a neurology-based NF clinic, we had more children with glioma, particularly optic pathway glioma, and more cerebral vasculopathy than has been reported in studies done in genetics-based clinics. 17 However, we would not expect to have a higher than typical prevalence of peripheral vascular disease or hypertension. Lastly, not all patients with identified vascular abnormalities were evaluated via conventional angiography. Magnetic resonance angiography is limited by spatial resolution and overestimation of stenosis. 28 In our study, most vasculopathy was noted on MRI and blood vessel imaging was simply confirmatory.
From this work, we can conclude that significant hypertension in a child with neurofibromatosis type 1 may indicate a renal or aortic vasculopathy. Furthermore, from this relatively small data set, it is apparent that there is not a strong association between peripheral vascular and cerebrovascular abnormalities in neurofibromatosis type 1; this study is underpowered to detect lesser associations.
There is an existing recommendation from 1 group of researchers that all children with neurofibromatosis type 1 who are undergoing neuroimaging should have a cerebral magnetic resonance angiography included in their studies because neurofibromatosis type 1 arteriopathy may be asymptomatic and potentially progressive. 5 The authors would add that while hypertension in children with neurofibromatosis type 1 is uncommon (6% of our study population), those with significant hypertension should be screened for renal and aortic vasculopathy. In our small sample, 40% of children with hypertension had a vascular cause. Awareness of vascular pathology in pediatric patients with neurofibromatosis type 1 is important not only for standard clinical care but it is a factor that should be considered when developing clinical trials and therapeutics for patients with neurofibromatosis type 1. For example, patients with known vascular disease will need special review when considering enrollment in clinical trials for their other neurofibromatosis type 1 manifestations with agents that may exacerbate vaso-occlusive disease (ie, antiangiogenesis agents). Conversely, some drugs currently in trial for plexiform neurofibroma (ie, imatinib) or cognitive processing (ie, lovastatin) may in fact positively impact vascular disease. 10, 29 
